Inamrinone Brand Name– Inocor
What is Inamrinone
Inamrinone (formerly amrinone) is a cyclic-AMP-dependent inotrope and vasodilator, which is given intravenously for the short-term management of congestive heart failure.
It belongs to a class of bipyridine inotropic/vasodilator agents, also referred to as inodilators. Inamrinone possesses positive inotropic and vasodilatory activity, with minimal chronotropic activity.
This agent differs in mechanism and structure from digoxin and the catecholamines. The ACC/AHA guidelines for management of chronic heart failure recommend that intermittent intravenous positive inotropic therapy has no proven value in patients with Stage C chronic heart failure (Class III recommendation); however, the guidelines suggest that continuous intravenous inotrope infusions may be considered for palliation of symptoms in patients with end-stage heart failure (i.e., Stage D).
Amrinone was first approved by the FDA in July 1984, and was renamed inamrinone (effective July 1, 2000).
Under the General Agreement on Tariffs and Trade (GATT), the original patent expired on October 14, 1995.
Indications
- heart failure
For the acute treatment of congestive heart failure, including postoperative cardiovascular surgery patients
Side Effects
- diarrhea
- elevated hepatic enzymes
- hypokalemia
- hypotension
- jaundice
- nausea
- thrombocytopenia
- ventricular tachycardia
- vomiting
Monitoring Parameters
- LFTs
- platelet count
- serum creatinine/BUN
Contraindications
- breast-feeding
- electrolyte imbalance
- hepatic disease
- hypokalemia
- idiopathic hypertrophic subaortic stenosis
- pregnancy
- renal disease
- renal failure
- renal impairment
- sulfite hypersensitivity
- valvular heart disease
Interactions
- Acetazolamide
- Anagrelide
- Carbonic anhydrase inhibitors
- Disopyramide
- Gallium Ga 68 Dotatate
- Ginger, Zingiber officinale
- Loop diuretics
- Mannitol
- Methazolamide
- Potassium-sparing diuretics
- Thiazide diuretics
- Urea
